Showing results (1181-1190 of 1,427) with videos related to

Sort By:
Pageof 143
Journal of Medicinal Chemistry|August 21, 2015
Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo ActivityEdward J Hennessy, Vibha Oza, Ammar Adam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2020
A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian CancerAmit M Oza, Maria Estevez-Diz, Eva-Maria Grischke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2011
Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomasAnastasios Stathis, Sebastien J Hotte, Eric X Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2009
Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumorsRuth Plummer, Laura Vidal, Melanie Griffin, et al.
Oncotarget|April 29, 2017
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancerSaeed Rafii, Charlie Gourley, Rajiv Kumar, et al.
Gynecologic Oncology|March 15, 2015
A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortiaIvan Diaz-Padilla, Michelle K Wilson, Blaise A Clarke, et al.
Gynecologic Oncology|November 13, 2024
Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancerKatherine Elizabeth Francis, Sandy Simon, Val Gebski, et al.
Nature Communications|September 28, 2024
Hypoxia induces ROS-resistant memory upon reoxygenation in vivo promoting metastasis in part via MUC1-CInês Godet, Harsh H Oza, Yi Shi, et al.
Gynecologic Oncology|October 15, 2023
A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancerSileny N Han, Amit Oza, Nicoletta Colombo, et al.
International Journal of Breast Cancer|June 15, 2026
Preliminary Effectiveness of the Comprehensive Oncology Rehabilitation and Exercise (CORE) Clinical Workflow Algorithm on Health Outcomes During Nonmetastatic Breast Cancer CareLea Haverbeck Simon, Carson Saviers-Steiger, Emily R Dunston, et al.
Pageof 143